Triphala is an Ayurvedic herbal formulation used to treat gastrointestinal disorders. The present study explored the underlying mechanisms of Ayurvedic formulation Triphala against integrated gastrointestinal and neurological disorders through network pharmacology and molecular docking. Components of Triphala were screened using Dr. Duke’s Phytochemical and Ethnobotanical Database, KNApSAcK database, and Indian Medicinal Plants, Phytochemistry and Therapeutics database while target prediction was done using SuperPred 3.0, followed by mapping with shared gastrointestinal and neurological disorders targets obtained from GeneCards and DisGenet databases. STRING and Cytoscape were utilized for protein–protein and protein-target interaction analyses and further screening of core clusters. GO, KEGG, and Reactome enrichment analysis were performed, and top targets were subject to binding affinity evaluation with major Triphala compounds. Based on ADME characteristics, seven screened Triphala components overlapped with 104 genes of gastrointestinal and neurological disorders. STAT3, ESR1, HIF1A, MTOR, PPARG, MAP2K2, TLR4, SLC2A1, NFKB1, and ESR1 were revealed as major interacting nodes through protein–protein interaction, compound-target interaction, and compound-target-disease-pathway network analysis. GO enrichment indicated genes involved in managing cell response to stress, stimuli, and metabolism while KEGG enrichment revealed pathways related to cancer, metabolism, and signalling. Reactome analysis implied an enrichment of the immune system, cell signalling, and disease pathways. Thannilignan, 7-Hydroxy-3',4'-methylenedioxyflavan, and Termilignan were identified as major phytocompounds of Triphala. Molecular docking indicated excellent interactions of Triphala components with all analysed receptors with mean binding energies ranging from − 7.58 to − 8.34 kcal/mol/receptor which was most notable in the compound 7-Hydroxy-3',4'-methylenedioxyflavan. Together, this work delineates the mechanisms of Triphala and identifies new drug candidates for the integrated management of gastrointestinal and neurological disorders.
Read full abstract